Company intelligence / Profile preview

TD

New York, New York, USA

Ownership: Private
Employees: ~352
Development stage: Other

Overview

TG Therapeutics has commercialized BRIUMVI (ublituximab), a monoclonal antibody for relapsing forms of multiple sclerosis, with expanding indications and strong commercial performance. The company has recently acquired rights to a CAR-T cell therapy candidate from Precision BioSciences, broadening its late-stage pipeline.[2][3]

Therapeutic areas: HematologyNeurology
Modalities: Monoclonal antibodyCell therapy
Industry: Biotech

Partnerships

Neuraxpharm Group (European BRIUMVI commercialization)Precision BioSciences (CAR-T cell therapy licensing agreement)

Beyond the preview

Go deeper on TD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TD.

Explore the full profile